IBM’s $11 Billion Quantum Bet in India and Lab 12,635 Atoms Deep — But Consulting Malaise Looms Over July 22 Earnings

IBM's quantum bets: India's first quantum computer and €2B Anderon chip subsidiary. But consulting grows just 1% as generative AI threatens legacy modernization. Stock near 52-week high, analysts see upside.

IBM is placing two huge chips on the future of computing, even as its traditional consulting business shows signs of fatigue. The company announced on July 2 that it will install one of India’s first quantum computers in Amaravati, Andhra Pradesh, with operations slated to start in September 2026. Chief executive Arvind Krishna has described the city as the nucleus of a nascent “Quantum Valley,” a research hub that will bring together universities, startups and industrial partners such as Tata Consultancy Services.

That India push sits alongside a far more capital-intensive bet on home soil. Together with the US government, IBM has launched a quantum?chip subsidiary called Anderon, capitalised at €2 billion. Under the code?name Project Starling, the company plans to sink an additional €9 billion into the technology by 2029, with the ultimate goal of building a fault?tolerant quantum computer.

Progress in the lab reinforces the ambition. IBM’s researchers recently simulated the behaviour of 12,635 atoms in a biomedical application, a leap from just ten atoms the previous year. The group has also unveiled a chip architecture based on 0.7?nanometre technology, though commercial production remains at least five years away. Such breakthroughs help underpin the stock’s technical position: the equity has held comfortably above its 200?day moving average.

The share price closed at €253.00 on Thursday, up 6.39% over the preceding week. That rally has narrowed the distance to the 52?week high of €292.85, reached on June 1, to 13.61%. The stock’s year?to?date gain stands at 1.75%, and the 14?day relative strength index of 63.4 suggests the move is not yet overbought. Analysts see further upside: the average price target on the US?listed shares is $306.76, while a separate consensus of European?based strategists puts the equivalent target at roughly €257, implying only modest near?term appreciation.

The stock’s trajectory, however, is being tugged in opposite directions by two underlying trends. On one side, the quantum narrative is drawing institutional interest, partly because IBM offers one of the few sizeable tech dividends. On the other, the core consulting business — a cash cow for decades — faces an accelerating threat from generative AI. Tools such as Claude Code can modernise legacy COBOL applications almost autonomously, undermining the very IT?modernisation projects that have long filled IBM’s consulting pipeline.

That tension showed up in the first quarter of 2026, which IBM reported with currency?adjusted revenue growth of 6% to $15.9 billion. Software climbed 11% and infrastructure surged 15%, but consulting expanded at just 1% in constant currency. The company held to its full?year forecast of currency?adjusted revenue growth above 5% and a free?cash?flow increase of roughly $1 billion. The new AI platform watsonx is meant to help fill the gap, but its contribution has yet to register in a meaningful way.

The next major test comes on July 22, when IBM delivers second?quarter earnings. Analysts expect adjusted earnings per share of approximately $2.95 on revenue of about $17.86 billion. The management team must also show that its revamped talent strategy is taking hold: the company intends to hire three times as many university graduates in 2026 as it did previously, hoping to inject fresh skills into the organisation before the old revenue streams dry up.

Between the India announcement and the earnings report, the stock sits in a delicate balancing phase. A solid quarterly beat could extend the recovery, but any miss on revenue or cash?flow guidance would put the recent rally to the test — and remind investors that quantum’s promise, however dazzling, remains years from delivering a commercial payoff.